Using antler extract to prevent breast precancerous lesions from becoming cancer
Antler Plate on Preventing Mammary High-risk Lesions From Malignant Development
Jilin University · NCT04440683
This study is testing if antler extract can help prevent breast precancerous lesions from turning into cancer in women aged 18 to 80 who have been diagnosed with certain breast conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6000 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | Female |
| Sponsor | Jilin University (other) |
| Locations | 1 site (Changchun, Jilin) |
| Trial ID | NCT04440683 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the effectiveness of antler disk extract in preventing the progression of breast precancerous lesions into cancer. It focuses on women aged 18 to 80 who have been diagnosed with atypical hyperplasia or lobular carcinoma in situ. The study builds on previous findings that antler ingredients can treat breast hyperplasia and may have a preventive effect against breast cancer. Participants will be monitored for compliance with treatment and follow-up protocols.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 18 to 80 with atypical hyperplasia or lobular carcinoma in situ and a family history of breast cancer.
Not a fit: Patients with significant liver or kidney dysfunction, cardiovascular or cerebrovascular diseases, or those deemed unsuitable by researchers may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a new preventive treatment option for women at high risk of developing breast cancer.
How similar studies have performed: While this approach is based on previous basic research, it is relatively novel in clinical practice and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women between the ages of 18 and 80 * Atypical hyperplasia or / and lobular carcinoma in situ confirmed by breast histology * Women with breast cancer in first degree relatives * Patients have better compliance with a series of research-related behaviors such as the upcoming comprehensive treatment and follow-up, and can understand and accept the research process of this study, and sign a written informed consent Exclusion Criteria: * Hepatorenal dysfunction, cardiovascular and cerebrovascular diseases * Patients not suitable for this study judged by researchers
Where this trial is running
Changchun, Jilin
- First Hospital of Jilin University — Changchun, Jilin, China (RECRUITING)
Study contacts
- Principal investigator: Aiping Shi, Doctor — The First Hospital of Jilin University
- Study coordinator: Di Wu, Doctor
- Email: w2000mail@sohu.com
- Phone: 0086-13504331975
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Breast Cancer Prevention